Safety of Guselkumab Treatment for up to 5 Years in Patients With Moderate-to-Severe Psoriasis: Pooled Analyses Across Seven Clinical Trials With Greater Than 8600 Patient-Years of Exposure.

Mark G LebwohlJoseph F MerolaKatelyn RowlandMegan MillerYa-Wen YangJenny YuYin YouDaphne ChanDiamant ThaҫiRichard G Langley

Published in: The British journal of dermatology (2023)

In this comprehensive analysis of 2891 guselkumab-treated patients with psoriasis followed for up to 5 years (8662 PY), guselkumab demonstrated favourable safety, consistent with previous reports. Safety event rates in guselkumab-treated patients were similar to those observed with placebo and were consistent throughout long-term treatment.

Keyphrases

clinical trial
newly diagnosed
end stage renal disease
chronic kidney disease
ejection fraction
randomized controlled trial
emergency department
open label
phase iii
replacement therapy
high intensity
phase ii
adverse drug